ReviewInfectious disease reports2025
Public Health Impact of the MVA-BN Vaccine During the 2022 Mpox Outbreak: A Systematic Review.
Review in Infectious disease reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND/
objectivesPreviously endemic to sub-Saharan Africa, mpox has since emerged globally, resulting in more than 150,000 cases in over 100 countries in the 2022 outbreak. The Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is licensed and recommended for at-risk populations in many countries and received World Health Organization (WHO) pre-qualification in September 2024.
methodsWe conducted this systematic literature review (SLR) to compare analyses, published from 2022 through 2024, of cases averted due to mpox vaccination during the 2022 outbreak to assess the feasibility of estimating the impact on the United States (US). The search included studies that utilized reported case data from any country.
resultsNine studies were identified. Four estimated the impact of the vaccine as directly modeled in the 2022 outbreak, and cases averted ranged from 10% to 79%. One assessed the projected impact on future outbreaks. Four estimated the impact of hypothetical vaccination strategies. Only one model utilized assumptions appropriate for the US outbreak and population, to allow for an estimate of US cases averted (53,499 cases averted due to the synergistic effects of the vaccine and behavioral changes, with 8096 due to the mpox vaccine alone and 5478 due to behavioral changes alone).
conclusionsVariation in estimates for the impact of the vaccine can typically be explained by differing model approaches, assumptions, inputs, and epidemic peaks and vaccination campaign roll-out. Most models were not generalizable to the US outbreak and population, but one yielded a reasonable estimate. Nevertheless, all models emphasized the importance of vaccination combined with other public health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.